Mitsubishi Tanabe Pharma Corp. is buying Israel-based Neuroderm Ltd., the developer of a belt-worn pump for the continuous delivery of liquid levodopa/carbidopa to treat severe Parkinson's disease (PD), for $1.1 billion in cash, or $39 per share. The deal is expected to play a key role in helping the Japanese company reach its goal of earning ¥80 billion (US$719.5 million) in U.S. revenue by 2020, in part by expanding its U.S. neurology portfolio. Read More
